| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
|
Proc Natl Acad Sci U S A
|
2010
|
3.86
|
|
2
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
J Clin Oncol
|
2007
|
2.64
|
|
3
|
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
|
Blood
|
2004
|
2.37
|
|
4
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
Blood
|
2007
|
2.15
|
|
5
|
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
|
Blood
|
2006
|
1.82
|
|
6
|
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
|
Blood
|
2005
|
1.73
|
|
7
|
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
|
J Clin Invest
|
2013
|
1.72
|
|
8
|
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
|
Haematologica
|
2013
|
1.36
|
|
9
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
10
|
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
|
J Clin Oncol
|
2010
|
1.20
|
|
11
|
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
|
Haematologica
|
2010
|
1.17
|
|
12
|
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
|
Cancer
|
2007
|
1.11
|
|
13
|
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
|
J Pharmacol Exp Ther
|
2007
|
1.06
|
|
14
|
Acute Lymphoblastic Leukemia, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.92
|
|
15
|
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.86
|
|
16
|
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.78
|